Approval · Notice of Compliance 18997 · 2017
NAROPIN: Notice of Compliance 18997
Issued February 20, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18997
- Date
- February 20, 2017
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to outer label to increase overall size of carton and to change carton orientation
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAROPIN | Not yet assigned | — |
Medicinal ingredients
- ROPIVACAINE HYDROCHLORIDE 5 MG per ML
- ROPIVACAINE HYDROCHLORIDE 10 MG per ML